三七有效成分对人子宫内膜细胞培养液6-keto-PGF1α、TXB2的影响

目的观察三七不同有效成分对人子宫内膜细胞炎症细胞模型细胞培养液中6-酮-前列腺素F1α（6-Keto-PGF1α）和血栓素B2（TXB2）含量的影响。方法利用细菌脂多糖（LPS）诱导正常子宫内膜细胞，导致细胞发生炎症反应的体外细胞模型，以前期实验确定的最佳浓度的三七有效成分干预炎症子宫内膜细胞模型，测定其两个时间段（48、72h）的6-Keto-PGF1α、TXB2的含量。结果三七复方成分能使6-Keto-PGF1α含量降低，TXB2含量增高，6-Keto-PGF1α／TXB2比值趋于正常。结论调整6-Keto-PGF1α／TXB2比值，恢复PGI2和TXA2之间的动态平衡，是三七复方成分防治炎症性子宫异常出血的有效途径之一。     

组胺受体激动剂对粒单核白血病细胞（WEHI－3）增殖的影响

用体外琼脂培养方法，检测经不同浓庆组胺Ｈ１受体激动剂，Ｈ２受体激动剂及其拮抗剂孵育的粒单核白血病细胞集落数。结果显示：组胺Ｈ１受体激动剂对白血病细胞集落数无明显影响；组胺Ｈ２受体激动剂ｉｍｐｒｏｍｉｄｉｎｅ１Ｏ￣５～１０－８ｍｏ１／Ｌ逍度范围内可明显增加集落数，１０－６ｍｏ１／Ｌ时集落数最高；Ｈ２受体拮抗剂甲氰咪胍可阻断这一效应。提示粒单核白血病细胞也存在在组胺Ｈ２受体，激动组胺Ｈ２全体可促进粒单核白血病细胞的进一步增殖。     

桃仁乙醇提取物对小鼠出血时间和凝血时间的影响

[目的]探讨桃仁乙醇提取物对小鼠出血时间和凝血时间的影响.[方法]取小鼠随机分为对照组、桃仁乙醇提取物大、中、小(2.4,1.2,0.6g/kg)剂量组,分别给予相应药物,15d后采用玻片法、毛细玻管法及断尾法测定小鼠凝血时间及出血时间.[结果]桃仁乙醇提取物大、中剂量组小鼠出血时间和凝血时间均明显延长.[结论]桃仁乙醇提取物具有抗凝血作用.     

乳头状甲状腺癌与促甲状腺激素受体第三胞内环基因突变的研究

目的探讨乳头状甲状腺癌的发病是否与促甲状腺激素受体(TSHR)第3胞内环基因突变相关。方法采用多聚酶联反应-单链构象多态性分析(PCR-SSCP)和DNA测序方法,对65例乳头状甲状腺癌和44例正常甲状腺组织TSHR第3胞内环基因进行检测。结果经PCR-SSCP检测乳头状甲状腺癌促甲状腺激素受体(TSHR)第3胞内环未发现明显带型异常;取2例对照组织和3例甲状腺癌组织进行DNA测序,TSHR2000位点碱基均由C→T,使得所编码的601位氨基酸由组氨酸(CAT)→酪氨酸(TAT)突变(His→Tyr),余未发现其他基因突变。结论乳头状甲状腺癌发病与TSHR第3胞内环基因突变无关;中国人TSHR基因与国外人群存在多态性差异。     

The functional characterization of interleukin-10 receptor expression on human natural killer cells

Human natural killer (NK) cells are large granular lymphocytes that constitutively express functional forms of the interleukin-2 receptor (IL-2R) and lyse tumor and virally infected cells without prior sensitization. NK cells with high density expression of CD56 (CD56bright) express the high affinity IL-2R and proliferate in response to low (picomolar) concentrations of IL-2. CD56dim NK cells express the intermediate affinity IL-2R and demonstrate enhanced cytotoxic activity without proliferation in response to high (nanomolar) concentrations of IL-2. In the present study, we characterized IL-10R expression on human NK cells and the functional consequences of IL-10 binding directly to highly purified subsets of CD56bright and CD56dim NK cells. Binding studies using 125I-IL-10 indicated that resting human NK cells constitutively express the IL-10 receptor protein at a surface density of approximately 90 receptor sites per cell, with a kd of approximately 1 nmol/L. Alone, IL-10 did not induce proliferation of CD56bright or CD56dim NK cell subsets. However, at low concentrations (0.5 to 5 ng/mL), IL-10 significantly augmented IL-2-induced proliferation of the CD56bright NK cell subset mediated via the high-affinity IL-2R. In the absence of IL-2, IL-10 was able to induce significant NK cytotoxic activity against NK-resistant tumor cell targets in both subsets of NK cells in a dose-dependent fashion. Furthermore, the combination of IL-10 and IL-2 had an additive effect on NK cytotoxic activity, whereas that of IL-10 and IL-12 did not. Production of interferon-gamma, tumor necrosis factor-alpha, and granulocyte-macrophage colony-stimulating factor by IL-2-activated NK cells was also significantly enhanced by IL-10. Neither resting nor activated human NK cells appear to produce human IL-10 protein. In summary, NK cells constitutively express the IL-10R protein in low density, and the functional consequences of IL-10 binding directly to human NK cell subsets appear to be stimulatory and dose-dependent. In contrast to its direct effects on human T cells and monocytes/macrophages, IL-10 potentiates cytokine production by human NK cells.     

Expression of ADAM8 and its clinical values in diagnosis and prognosis of hepatocellular carcinoma

ADAM8 behaves as an active metalloprotease in vitro, hydrolyzing myelin basic protein and a variety of peptide substrates based on the cleavage sites of membrane-bound cytokines, growth factors, and receptors. Other studies have demonstrated overexpression of some ADAM family proteins in a variety of human tumors, but no report is available on the actual expression of ADAM8 and the correlation between clinicopathologic features and prognosis of hepatocellular carcinoma (HCC) patients. In this study, serum levels of ADAM8 were measured by ELISA in 126 patients with HCC, 50 patients with liver cirrhosis (LC), and 50 healthy individuals. The expression of ADAM8 in liver tissue was further studied using Western blotting in 126 patients with HCC and 50 with LC. The correlations between ADAM8 status and various clinicopathological parameters including survival were analyzed. Survival analysis was performed using the Kaplan?CMeier method and Cox's proportional hazards model. The ELISA assay showed that the serum levels of ADAM8 in the HCC, LC, and healthy groups were 136.4?±?34.5, 64.2?±?20.1, and 63.2?±?22.7?U/ml, respectively. Analysis of variance was used for inter-group comparison, and differences were found between the HCC group and the other two groups (both P?<?0.001), while no difference was found between the LC group and the healthy group (P?=?0.365). Western blotting assay showed that ADAM8 protein expression was detected in 62.7?% (79/126) HCC and in 32?% (16/50) LC tissues. Further, ADAM8 expression was associated closely with serum AFP elevation, tumor size, histological differentiation, tumor recurrence, tumor metastasis, and tumor stage. Kaplan?CMeier survival analysis showed that patients with ADAM8-positive tumors had a shorter postoperative survival time than those with ADAM8-negative tumors (P?<?0.001). Multivariate analysis revealed that ADAM8 expression was an independent prognostic parameter for the overall survival rate of HCC patients. These findings provide evidence that the expression of ADAM8 serves as a poor prognostic biomarker for HCC. ADAM8 may be a potential target of antiangiogenic therapy for HCC.     

HLA与HPV相关肿瘤的研究进展

人乳头状瘤病毒（HPV）感染是宫颈癌等肿瘤的高危因素,其致瘤机制尚未完全阐明。在免疫应答过程中,机体HLA-I,Ⅱ,Ⅲ类分子表达异常与HPV相关肿瘤免疫逃避有关,可为宫颈癌、食管癌等肿瘤的病因学提供新的线索。